Sign in Subscribe

Biomedical Innovation

New therapies, medical breakthroughs, emerging technologies

A New Hypothesis to explain Alzheimer’s disease

A New Hypothesis to explain Alzheimer’s disease

SPECIAL REPORT 24.09 Alzheimer’s disease (AD) is a complex neurodegenerative disease that develops over many years before the first clinical symptoms appear. The disease progressively attacks neurons and their environment which triggers memory loss. In 1991, John Hardy has postulated that the trigger of the disease was due

EMA does not recommend Leqembi for the treatment of Alzheimer’s disease

EMA does not recommend Leqembi for the treatment of Alzheimer’s disease

SPECIAL REPORT 24.07 EMA does not recommend Leqembi for the treatment of Alzheimer’s disease On July 25, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended against marketing authorisation of BioArtic, Eisai and Biogen’s Lequembi, or lecanemab, an amyloid antibody

Eli Lilly wins FDA approval for donanamab

Eli Lilly wins FDA approval for donanamab

After decades of trying to develop a treatment for Alzheimer’s disease, Eli Lilly has finally won FDA approval for its drug donanemab, which will be marketed as Kisunla. An approval was originally expected late last year, but it was delayed twice, including after regulators called for an 11th-hour meeting

FDA Advisory Committee recommends approval of Eli Lilly donanemab

FDA Advisory Committee recommends approval of Eli Lilly donanemab

SPECIAL REPORT 24.06 US FDA Advisory Committee recommends approval of Eli Lilly donanemab On June 10, 2024, the US FDA Peripheral and Central Nervous System Drugs Advisory Committee panel recommended approval of Eli Lilly’s donanemab for the treatment of early-stage Alzheimer’s disease. The panel voted 11-0 that

An Approval and an Inventive Step in Alzheimer’s Disease.

An Approval and an Inventive Step in Alzheimer’s Disease.

SPECIAL REPORT An Approval and an Inventive Step in Alzheimer’s Disease.

Alzheimer’s Disease Conundrum

Alzheimer’s Disease Conundrum

The following article and its associated commentary were published in the February 2023 edition of MedNous.

The Alzheimer’s puzzle isn’t yet solved.

The Alzheimer’s puzzle isn’t yet solved.

Commentary The Alzheimer’s puzzle isn’t yet solved.